WO2018066690A1 - シチジンジリン酸コリンの結晶及びその製造方法 - Google Patents
シチジンジリン酸コリンの結晶及びその製造方法 Download PDFInfo
- Publication number
- WO2018066690A1 WO2018066690A1 PCT/JP2017/036463 JP2017036463W WO2018066690A1 WO 2018066690 A1 WO2018066690 A1 WO 2018066690A1 JP 2017036463 W JP2017036463 W JP 2017036463W WO 2018066690 A1 WO2018066690 A1 WO 2018066690A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytidine diphosphate
- crystal
- crystals
- organic solvent
- choline
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 202
- 229960001284 citicoline Drugs 0.000 title claims abstract description 108
- 238000004519 manufacturing process Methods 0.000 title claims description 19
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 title abstract 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 201
- 239000003960 organic solvent Substances 0.000 claims abstract description 69
- 239000007864 aqueous solution Substances 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000008569 process Effects 0.000 claims abstract description 7
- 230000001376 precipitating effect Effects 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 138
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 claims description 101
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 36
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 238000002425 crystallisation Methods 0.000 claims description 21
- 230000008025 crystallization Effects 0.000 claims description 21
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 18
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 17
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 6
- 229940011051 isopropyl acetate Drugs 0.000 claims description 6
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 6
- 229940032007 methylethyl ketone Drugs 0.000 claims description 6
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 6
- 229940090181 propyl acetate Drugs 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 abstract description 21
- 238000005406 washing Methods 0.000 abstract description 19
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 229960001231 choline Drugs 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000010079 rubber tapping Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 125000002740 cytidyl group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- BRFMYUCUGXFMIO-UHFFFAOYSA-N phosphono dihydrogen phosphate phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O BRFMYUCUGXFMIO-UHFFFAOYSA-N 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005464 sample preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a crystal of cytidine diphosphate choline having excellent quality and a method for producing the same.
- Cytidine diphosphate choline is a physiologically active substance having an effect of improving brain function, and is widely used as a medical drug in Japan and as a health food material overseas (Patent Document 1).
- a crystal of cytidine diphosphate choline a monohydrate crystal is known (Patent Document 3).
- Patent Documents 2 and 3 As a method for producing the crystal, a method of adding an organic solvent to an aqueous solution in which cytidine diphosphate choline is dissolved is disclosed.
- Non-Patent Document 1 methanol is designated as a class 2 as a solvent whose residual amount in pharmaceuticals should be regulated, and it is not desirable to remain in foods that are outside the scope of doctors' prescription management. Therefore, cytidine diphosphate choline crystals are strongly demanded to reduce residual methanol as a material used in pharmaceuticals and foods, and it is also required to have good powder physical properties for molding into tablets etc. It is done.
- Japanese Patent No. 6166786 Japanese Patent Publication No. 51-32630 Japanese Patent No. 647367 Japanese Patent No. 3369236 Japanese Patent No. 4977608
- Patent Document 3 when trying to obtain crystals of cytidine diphosphate from an aqueous solution in which choline cytidine diphosphate is dissolved at a high temperature of 50 to 70 ° C. Cytidine diphosphate choline is easily decomposed, and impurities produced by the decomposition remain in the product at a high concentration (Patent Document 3 and Comparative Example 3 in Table 3 described later).
- methanol used in the crystallization step remains in the crystal at a high concentration without using methanol in the washing step when the crystal is separated by filtration (comparison of Table 4 described later). Examples 1 and 2).
- Cytidine diphosphate which is currently available in the market, has a residual amount of methanol (product of companies A to C in Table 4 to be described later) and does not contain methanol and has excellent powder properties.
- the choline crystals have not been known so far.
- an object of the present invention is to provide a cytidine diphosphate choline crystal that does not contain methanol and has improved powder physical properties, and a method for producing the same.
- the present invention relates to the following (1) to (11).
- a step of precipitating choline cytidine diphosphate crystals in an aqueous solution in which cytidine diphosphate choline is dissolved, a step of collecting the precipitated crystals of choline diphosphate phosphate, and a sample of the collected crystals of choline diphosphate phosphate having a water content A method for producing crystals of cytidine diphosphate choline, comprising a step of washing with an aqueous solution containing an organic solvent other than methanol at 5 to 50% by volume.
- the organic solvent other than methanol is selected from the group consisting of ethanol, acetone, 1-propanol, 2-propanol, ethyl acetate, 1-butanol, 2-butanol, heptane, isopropyl acetate, methyl ethyl ketone, propyl acetate and tetrahydrofuran.
- the production method according to (8), wherein the production method is at least one organic solvent.
- the production method according to the above (8) or (9), wherein the organic solvent other than methanol is at least one organic solvent selected from the group consisting of ethanol, acetone, 1-propanol and 2-propanol.
- (11) The production method according to any one of (8) to (10) above, wherein the organic solvent other than methanol is ethanol.
- the present invention provides a crystal of cytidine diphosphate choline that does not contain methanol and has improved powder properties, and a method for producing the same.
- FIG. 1 shows the correlation between the crude specific volume and the ethanol concentration of the aqueous ethanol solution used for crystal washing for the crystals of cytidine diphosphate choline obtained in Comparative Examples 3 and 4 and Examples 1 to 4.
- the vertical axis represents the crude specific volume (mL / g), and the horizontal axis represents the ethanol concentration (% by volume).
- the black diamond represents the result of crystallization at 70 ° C.
- the white diamond represents the result of crystallization at 30 ° C.
- FIG. 2 shows the correlation between the dense specific volume and the ethanol concentration of the aqueous ethanol solution used for crystal washing for the crystals of cytidine diphosphate choline obtained in Comparative Examples 3 and 4 and Examples 1 to 4.
- the vertical axis represents the dense specific volume (mL / g), and the horizontal axis represents the ethanol concentration (% by volume).
- the black diamond represents the result of crystallization at 70 ° C.
- the white diamond represents the result of crystallization at 30 ° C.
- the crystal of the present invention is a crystal of choline cytidine diphosphate that does not contain methanol and has a crude specific volume of 4.1 mL / g or less. As an embodiment of the crystal of the present invention, it does not contain methanol, and the crude specific volume is preferably 3.6 mL / g or less, more preferably 3.1 mL / g or less, and most preferably 2.6 mL / g or less. Mention may be made of crystals of cytidine diphosphate choline.
- the crystal of cytidine diphosphate choline preferably has a small crude specific volume, but the lower limit of the crude specific volume is usually 1.0 mL / g or more, preferably 1.2 mL / g or more. .
- the coarse specific volume means a value obtained by dividing the volume occupied by the powder when the container is filled with the powder and its mass is measured.
- the crude specific volume can be measured according to the 17th revised Japanese Pharmacopoeia using a multi-tester MT-1001T type (manufactured by Seishin Enterprise Co., Ltd.) according to the attached manual under the following conditions.
- the crystal of the present invention does not contain methanol, the crude specific volume is 4.1 mL / g or less, and the angle of repose is preferably 57 degrees or less, more preferably 55 degrees or less, still more preferably A cytidine diphosphate choline crystal of 53 degrees or less, most preferably 50 degrees or less can be mentioned.
- the crystal of cytidine diphosphate choline preferably has a small angle of repose, but the lower limit of the angle of repose is usually 30 degrees or more, preferably 35 degrees or more.
- the angle of repose refers to the angle formed between the generatrix of the cone formed by the powder and the horizontal plane when the powder is gently dropped onto a horizontal surface like a funnel.
- the repose angle can be measured under the following conditions using a multi-tester MT-1001T type (manufactured by Seishin Enterprise Co., Ltd.) according to the attached manual.
- the crystal of the present invention does not contain methanol, the crude specific volume is 4.1 mL / g or less, and the decay angle is preferably 50 degrees or less, more preferably 48 degrees or less, and still more preferably A cytidine diphosphate choline crystal of 46 degrees or less, most preferably 44 degrees or less can be mentioned.
- the lower limit of the collapse angle is usually 30 degrees or more, preferably 35 degrees or more.
- the decay angle is formed when a constant impact is indirectly applied to a cone formed by powder when the powder is gently dropped on a horizontal surface like a funnel.
- the collapse angle can be measured by the following method using a multi-tester MT-1001T type (manufactured by Seishin Enterprise Co., Ltd.) according to the attached manual.
- the crystal of the present invention does not contain methanol, the crude specific volume is 4.1 mL / g or less, and the dense specific volume is preferably 2.1 mL / g or less, more preferably 2.0 mL. / G or less, more preferably 1.9 mL / g or less, and most preferably 1.7 mL / g or less of cytidine diphosphate choline crystals.
- the crystal of cytidine diphosphate choline preferably has a small dense specific volume, but the lower limit of the dense specific volume is usually 0.8 mL / g or more, preferably 1.0 mL / g or more. .
- the dense specific volume refers to a value obtained by dividing the volume occupied by the powder when the mass is measured after the container is filled with the powder and a certain impact is applied.
- the dense specific volume can be measured under the following conditions using a multi-tester MT-1001T type (manufactured by Seishin Enterprise Co., Ltd.) according to the 17th revised Japanese Pharmacopoeia, for example.
- the difference between the repose angle and the collapse angle is preferably 9.0 or less, more preferably 8
- a crystal having a large difference between the repose angle and the collapse angle has a high jet property and is difficult to control. Therefore, it is preferable that the difference between the repose angle and the collapse angle is small.
- the crystal of the present invention does not contain methanol, has a crude specific volume of 4.1 mL / g or less, and preferably ethanol, acetone, 1-propanol, 2-propanol, ethyl acetate, 1-
- the organic solvent other than at least one organic solvent selected from the group most preferably a crystal of cytidine diphosphate that does not contain an organic solvent other than ethanol.
- methanol is not contained, the crude specific volume is 4.1 mL / g or less, and the content of the organic solvent contained in the crystal is preferably 1000 ppm by mass, respectively.
- crystals of cytidine diphosphate choline having 800 ppm by mass or less, more preferably 600 ppm by mass or less, and most preferably 500 ppm by mass or less can be exemplified.
- the content of the organic solvent in the crystal of the present invention can be measured, for example, by analysis using the gas chromatograph.
- methanol does not contain, the crude specific volume is 4.1 mL / g or less, and the peak area of cytidine diphosphate choline in high performance liquid chromatography (hereinafter referred to as HPLC) analysis.
- HPLC high performance liquid chromatography
- 5 'cytidyl acid is a compound produced by decomposition of choline cytidine diphosphate depending on heating or pH fluctuation.
- HPLC analysis means that a compound to be analyzed is dissolved in a solvent and subjected to analysis by HPLC.
- the HPLC analysis is not particularly limited as long as it is an analytical method capable of simultaneously detecting cytidine diphosphate choline, 5 ′ cytidyl acid, and uridine diphosphate choline, and preferably HPLC for detecting and measuring absorbance at 254 nm. Analytical methods can be mentioned.
- HPLC analysis methods include the HPLC analysis examples described below.
- the peak area in the HPLC analysis is a value when measured under the HPLC analysis conditions described in the above HPLC analysis example.
- the analysis conditions equivalent to the analysis conditions are also included in the HPLC analysis conditions in the present specification.
- the peak area refers to the area surrounded by the baseline and the peak line when HPLC analysis is performed, and can be determined for each compound detected by HPLC analysis.
- the peak of uridine diphosphate does not contain methanol, the crude specific volume is 4.1 mL / g or less, and the peak area of choline cytidine diphosphate is 100 in HPLC analysis.
- a cytidine diphosphate choline crystal having an area of preferably 0.56 or less, more preferably 0.30 or less, still more preferably 0.10 or less, and most preferably 0.06 or less can be given.
- Uridine diphosphate choline is a compound produced by decomposition of cytidine diphosphate choline depending on heating or pH fluctuation.
- the crystal production method of the present invention comprises a step of precipitating cytidine diphosphate choline crystals in an aqueous solution in which cytidine diphosphate choline is dissolved, a step of collecting the precipitated cytidine diphosphate choline crystals, and And washing the collected cytidine diphosphate choline crystals with an aqueous solution containing an organic solvent other than methanol having a water content of 5 to 50% by volume.
- the cytidine diphosphate choline contained in the aqueous solution in which cytidine diphosphate is dissolved may be produced by any production method such as a fermentation method, an enzymatic method, an extraction method from a natural product, or a chemical synthesis method. .
- Examples of a method for obtaining an aqueous solution in which cytidine diphosphate choline is dissolved include, for example, a method in which the obtained cytidine diphosphate choline is dissolved in water, and a cytidine diphosphate obtained by culturing a microorganism having the ability to produce cytidine diphosphate choline.
- Examples include a method for removing insoluble matter from a culture containing choline [Japanese Patent No. 3369236 (Patent Document 4)] and the like, and a method described in Japanese Patent No. 4777608 (Patent Document 5). it can.
- the solid matter can be removed by centrifugation, filtration, or a ceramic filter.
- the aqueous solution in which cytidine diphosphate choline is dissolved contains water-soluble impurities and salts that hinder crystallization
- the aqueous solution is removed by passing through a column packed with an ion exchange resin or the like. Impurities and salts can be removed.
- the hydrophobic solution can be obtained by passing through a column packed with synthetic adsorption resin or activated carbon. Impurities can be removed.
- the concentration of choline cytidine diphosphate in an aqueous solution in which cytidine diphosphate is dissolved can be adjusted to be preferably 200 g / L or more, more preferably 250 g / L or more, and even more preferably 300 g / L or more.
- the aqueous solution can be concentrated by a general concentration method such as a heat concentration method or a vacuum concentration method.
- Examples of a method for precipitating cytidine diphosphate choline crystals in an aqueous solution in which cytidine diphosphate choline is dissolved include, for example, a method of cooling the aqueous solution, a method of concentrating the aqueous solution under reduced pressure, an organic solvent other than methanol in the aqueous solution, Examples include a method of adding or dropping an aqueous solution containing an organic solvent, or a method of combining one or more of them, and an organic solvent other than methanol or an aqueous solution containing the organic solvent is added to the aqueous solution or The method of dripping is preferable and the method which combined the method of adding or dripping the organic solvent other than methanol or the aqueous solution containing this organic solvent in this aqueous solution, and the method of cooling this aqueous solution is more preferable.
- the temperature of the aqueous solution is preferably 0 to 35 ° C., more preferably 0 to 30 ° C., and most preferably 0 to 25 ° C.
- the cooling time is preferably 2 to 100 hours, more preferably 2 to 70 hours, and most preferably 2 to 50 hours.
- the temperature of the aqueous solution is preferably 0 to 50 ° C., more preferably 5 to 45 ° C., and most preferably 10 to 40 ° C. .
- the reduced pressure time is preferably 2 to 100 hours, more preferably 3 to 70 hours, and most preferably 5 to 50 hours.
- Examples of the organic solvent other than methanol in the method of adding or dropping an organic solvent other than methanol or an aqueous solution containing the organic solvent into an aqueous solution in which cytidine diphosphate choline is dissolved include, for example, preferably ethanol, acetone, 1- At least one organic solvent selected from the group consisting of propanol, 2-propanol, ethyl acetate, 1-butanol, 2-butanol, heptane, isopropyl acetate, methyl ethyl ketone, propyl acetate and tetrahydrofuran, more preferably ethanol, acetone, 1- As the at least one organic solvent selected from the group consisting of propanol and 2-propanol, ethanol is most preferable. Moreover, these organic solvents can also be used in combination of multiple types.
- the concentration of the organic solvent in the aqueous solution containing an organic solvent other than methanol, which is added or dropped into the aqueous solution in which cytidine diphosphate is dissolved is preferably 30% by volume or more, more preferably 40% by volume or more, More preferably, 50 volume% or more can be mentioned, Most preferably, 60 volume% or more can be mentioned.
- the temperature at which an organic solvent other than methanol or an aqueous solution containing the organic solvent is added or dropped is preferably 0 to 70 ° C., more preferably 0 to 50 ° C., still more preferably 5 to 45 ° C., most preferably 10 to 35 ° C. can be mentioned.
- the time required for addition or dropwise addition of an organic solvent other than methanol or an aqueous solution containing the organic solvent is preferably 1 to 10 hours, more preferably 2 to 8 hours.
- the amount of the organic solvent other than methanol or the aqueous solution containing the organic solvent added or dropped is preferably 1 to 10 times equivalent, more preferably 2 to 7 times equivalent of the aqueous solution in which cytidine diphosphate choline is dissolved. Can be mentioned.
- seed crystals may be added before the crystals of cytidine diphosphate choline are precipitated.
- seed crystals for example, crystals of cytidine diphosphate choline obtained by the method described in Japanese Patent No. 647367 (Patent Document 3) can be used.
- the time for adding the seed crystal is, for example, preferably within 0 to 12 hours, more preferably 0 to 8 hours from the start of dropping or addition of an organic solvent other than methanol or an aqueous solution containing the organic solvent. And most preferably within 0 to 4 hours.
- the seed crystal can be added so that the concentration in the aqueous solution to which the seed crystal is added is preferably 0.1 to 5.0 g / L, more preferably 0.2 to 1.0 g / L.
- cytidine diphosphate choline crystals as described above, preferably 0.5 to 48 hours, more preferably 0.5 to 24 hours, most preferably 0.5 to 12 hours, preferably 0 to 70. It can be aged by stirring or leaving the aqueous solution containing the crystals at a temperature of 0 ° C., more preferably 3 to 50 ° C., and most preferably 5 to 35 ° C.
- Aging the crystal means that the crystal is grown by interrupting or stopping the addition of an organic solvent other than methanol or an aqueous solution containing the organic solvent.
- Growing a crystal means increasing the crystal based on the precipitated crystal. Crystal ripening is performed mainly for the purpose of growing a crystal, but a new crystal may be precipitated simultaneously with the growth of the crystal. After aging the crystals, the step of precipitating cytidine diphosphate choline crystals may be resumed.
- Step of collecting precipitated cytidine diphosphate choline crystals Examples of methods for collecting precipitated cytidine diphosphate choline crystals include filtration, pressure filtration, suction filtration, and centrifugation.
- the collected cytidine diphosphate choline crystal is an organic substance other than methanol having a water content of 5 to 50% by volume, preferably 10 to 40% by volume, more preferably 20 to 30% by volume. Wash with aqueous solution containing solvent. According to this process, in addition to reducing the adhesion of the mother liquor to the crystal and improving the quality of the crystal, the powder physical properties of the crystal can be controlled.
- the temperature of the aqueous solution containing an organic solvent other than methanol used for crystal washing may be any temperature as long as the cytidine diphosphate choline is not decomposed, but is preferably 40 ° C. or lower, more preferably 30 ° C. or lower, still more preferably. 20 ° C. or lower, most preferably 15 ° C. or lower.
- 0 degreeC or more normally, Preferably 5 degreeC or more can be mentioned.
- an organic solvent other than methanol used in the step of washing crystals of cytidine diphosphate an organic solvent other than methanol or an aqueous solution containing the organic solvent is added or added dropwise to an aqueous solution in which the cytidine diphosphate choline is dissolved.
- an organic solvent similar to the organic solvent other than methanol can be used.
- Examples of the method for washing the crystal include a method for spraying or spraying a crystal washing solution comprising an aqueous solution containing an organic solvent other than the above-mentioned methanol on the crystal layer, and a method for immersing the crystal layer in the crystal washing solution. be able to.
- the crystal layer is taken out of the crystal cleaning solution in which the crystal layer is immersed, suspended again in the crystal cleaning solution, stirred, filtered again, pressure filtered, suction filtered, Operations such as centrifugation can also be performed.
- the amount of the crystal washing solution used for the crystal washing is preferably 0.5 to 10 times, more preferably 1 to 9 times, and further preferably 2 to 8 times by volume ratio of the cytidine diphosphate choline to the crystal weight. The amount can be mentioned.
- the crystals of the present invention can be obtained by drying the wet crystals thus obtained. Any drying method may be used as long as it can maintain the crystal form of cytidine diphosphate choline. For example, vacuum drying, vacuum drying, fluidized bed drying, ventilation drying, and the like can be applied.
- the drying temperature may be any as long as it can remove adhering moisture and solvent, but is preferably 80 ° C. or lower, more preferably 70 ° C. or lower, and most preferably 60 ° C. or lower.
- the drying time may be any as long as it can remove the adhering moisture and the solvent, but it is preferably 1 to 48 hours, more preferably 1 to 24 hours.
- Example 1 According to Example 1 of Japanese Patent Publication No. 51-32630 (patent document 2), 760 g of cytidine diphosphate choline (Kyowa Hakko Bio Co., Ltd .: Lot. 160325) was dissolved in distilled water to make 1600 mL, and cytidine diphosphate choline was 450 g. An aqueous solution containing a concentration of / L was prepared. 1400 mL of methanol was added over 20 minutes at 20 ° C. to 400 mL of them. When white turbidity was observed during the addition of methanol, 0.8 g of cytidine diphosphate choline was added as a seed crystal.
- Comparative Example 2 The rest of the crystal slurry obtained in Comparative Example 1 was centrifuged to separate the crystals, and the obtained wet crystals were suspended in 160 mL of 99.5% by volume ethanol and stirred to adhere to the crystal surface. Methanol was washed away completely. The wet crystals were dried under reduced pressure at 25 ° C. for 3 hours and further under reduced pressure at 60 ° C. for 3 hours to obtain 13.2 g of crystals.
- Example 3 According to Example 3 of Japanese Patent No. 647367 (Patent Document 3), 639.9 g of cytidine diphosphate choline (Kyowa Hakko Bio Co., Ltd .: Lot. 160325) in terms of dry matter was added to 1300 mL of distilled water and dissolved. 1690 mL aqueous solution. Of these, 832 mL was mixed with 640 mL of 99.5 vol% ethanol at 70 ° C. Subsequently, 1280 mL of 80% by volume hydrous ethanol was added over 2 hours while maintaining the mixed solution at 70 ° C.
- Patent Document 3 639.9 g of cytidine diphosphate choline (Kyowa Hakko Bio Co., Ltd .: Lot. 160325) in terms of dry matter was added to 1300 mL of distilled water and dissolved. 1690 mL aqueous solution. Of these, 832 mL was mixed with 640 mL of 99.5 vol%
- Example 1 One third of the crystal slurry obtained in Comparative Example 3 was centrifuged to separate the crystals, and then washed with 533 mL of 85 volume% aqueous ethanol (water content 15 volume%) cooled to 10 ° C. The obtained wet crystals were dried under reduced pressure at 30 ° C. for 3 hours and further under reduced pressure at 60 ° C. for 3 hours to obtain 68.2 g of crystals.
- Example 2 After centrifuging 1/3 minutes of the crystal slurry obtained in Comparative Example 3 to separate crystals, the crystals were washed with 533 mL of 70% by volume hydrous ethanol (water content 30% by volume) cooled to 10 ° C. The obtained wet crystals were dried under reduced pressure at 30 ° C. for 3 hours and further under reduced pressure at 60 ° C. for 3 hours to obtain 82.5 g of crystals.
- Example 3 One third of the crystal slurry obtained in Comparative Example 4 was centrifuged to separate the crystals, and then washed with 670 mL of 85% by volume hydrous ethanol (water content 15% by volume) cooled to 10 ° C. The obtained wet crystals were dried under reduced pressure at 30 ° C. for 3 hours and further under reduced pressure at 60 ° C. for 3 hours to obtain 109.6 g of crystals.
- Example 4 One third of the crystal slurry obtained in Comparative Example 4 was centrifuged to separate the crystals, and then washed with 670 mL of 70% by volume hydrous ethanol (water content 30% by volume) cooled to 10 ° C. The obtained wet crystals were dried under reduced pressure at 30 ° C. for 3 hours and further under reduced pressure at 60 ° C. for 3 hours to obtain 105.8 g of crystals.
- Fig. 1 shows the results of measuring the crude specific volume, dense specific volume, repose angle, and decay angle of cytidine diphosphate choline crystals currently on the market and cytidine diphosphate choline crystals obtained by the above method. It shows in FIG. 2 and Table 2, respectively.
- the specific volume of the cytidine diphosphate choline crystals was increased as the water content of the ethanol solution used for crystal washing was increased at both crystallization temperatures of 30 ° C. and 70 ° C. It was shown that the specific volume and dense specific volume) can be reduced. In particular, in crystallization at 30 ° C., which is a low temperature condition, the effect of reducing the specific volume by increasing the water content of the ethanol solution was more remarkable.
- Table 3 shows the results of measuring the amount of 5 'cytidyl acid and choline uridine diphosphate contained in the crystals of the obtained cytidine diphosphate choline by HPLC analysis. Each value in Table 3 shows the value of each peak area when the peak area of cytidine diphosphate choline is defined as 100.
- Table 4 shows the results of measuring the residual solvent contained in the crystals of cytidine diphosphate choline crystals and the obtained cytidine diphosphate crystals currently on the market by gas chromatography.
- ppm indicates mass ppm.
- ND indicates that it is below the detection limit.
- Comparative Examples 1 and 2 about 0.5 g of cytidine diphosphate choline crystals were weighed and dissolved in distilled water to adjust to 10 mL.
- Comparative Examples 3 and 4 and Examples 1 to 4 about 1 g of cytidine diphosphate choline crystals were weighed and dissolved in distilled water to adjust to 10 mL.
- the crystal production method of the present invention makes it possible to obtain a crystal of cytidine diphosphate that does not contain methanol and that exhibits a powder physical property equivalent to or higher than that of the existing cytidine diphosphate crystal.
- a crystal of cytidine diphosphate choline that achieves both reduction of impurities and residual solvent and improvement of powder physical properties, and a method for producing the same are provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)メタノールを含有せず、かつ粗比容が4.1mL/g以下である、シチジンジリン酸コリンの結晶。
(2)安息角が57度以下である、上記(1)に記載の結晶。
(3)崩壊角が50度以下である、上記(1)又は(2)に記載の結晶。
(4)密比容が2.1mL/g以下である、上記(1)~(3)のいずれか1に記載の結晶。
(5)エタノール、アセトン、1-プロパノール、2-プロパノール、酢酸エチル、1-ブタノール、2-ブタノール、ヘプタン、酢酸イソプロピル、メチルエチルケトン、酢酸プロピル及びテトラヒドロフランからなる群より選ばれる少なくとも1の有機溶媒以外の有機溶媒を含有しない、上記(1)~(4)のいずれか1に記載の結晶。
(6)エタノール、アセトン、1-プロパノール及び2-プロパノールからなる群より選ばれる少なくとも1の有機溶媒以外の有機溶媒を含有しない、上記(1)~(5)のいずれか1に記載の結晶。
(7)エタノール以外の有機溶媒を含有しない、上記(1)~(6)のいずれか1に記載の結晶。
(8)シチジンジリン酸コリンが溶解している水溶液にシチジンジリン酸コリンの結晶を析出させる工程、該析出したシチジンジリン酸コリンの結晶を採取する工程、及び該採取したシチジンジリン酸コリンの結晶を、含水量が5~50体積%である、メタノール以外の有機溶媒を含有する水溶液で洗浄する工程を含む、シチジンジリン酸コリンの結晶の製造方法。
(9)メタノール以外の有機溶媒が、エタノール、アセトン、1-プロパノール、2-プロパノール、酢酸エチル、1-ブタノール、2-ブタノール、ヘプタン、酢酸イソプロピル、メチルエチルケトン、酢酸プロピル及びテトラヒドロフランからなる群より選ばれる少なくとも1の有機溶媒である、上記(8)に記載の製造方法。
(10)メタノール以外の有機溶媒が、エタノール、アセトン、1-プロパノール及び2-プロパノールからなる群より選ばれる少なくとも1の有機溶媒である、上記(8)又は(9)に記載の製造方法。
(11)メタノール以外の有機溶媒が、エタノールである、上記(8)~(10)のいずれか1に記載の製造方法。
本発明の結晶は、メタノールを含有せず、かつ粗比容が4.1mL/g以下である、シチジンジリン酸コリンの結晶である。
本発明の結晶の一態様としては、メタノールを含有せず、かつ粗比容が好ましくは3.6mL/g以下、より好ましくは3.1mL/g以下、最も好ましくは2.6mL/g以下のシチジンジリン酸コリンの結晶を挙げることができる。
使用機器:マルチテスターMT-1001T型(セイシン企業社製)
ふるい:1.18mm
振動幅:0.7~0.8mm
結晶容量:100mL
粗比容の測定方法の具体例:0.7~0.8mmの幅で振動させた1.18mmのふるいを経由して結晶を落下させながら、ステンレス製の100mL円筒形容器に充填する。容器の上面から過剰の粉体を注意深く擦り落とし、あらかじめ測定しておいた空の測定容器の質量を差し引くことで、粉体の質量を測定する。測定は独立して3回行い、平均値を求める。
使用機器:GC-2014(島津製作所社製)
カラム充填剤:Adsorb P-1 60/80mesh(西尾工業社製)
カラム温度:120℃
気化室温度:150℃
ヘリウム流速:30mL/min
検出器温度:200℃試料調製方法:シチジンジリン酸コリンの結晶を約1.0g秤量し、蒸留水に溶解させて10mLに調整したものを試料とする。
使用機器:マルチテスターMT-1001T型(セイシン企業社製)
ふるい:1.18mm
振動幅:0.7~0.8mm
安息角の測定方法の具体例:0.7~0.8mmの幅で振動させた1.18mmのふるいを経由して結晶を落下させながら、安息角テーブル(部品番号:MT-1028)の上に堆積させる。安息角テーブルに振動を与えないように回転させて、3ヶ所で角度を読み、それらの相加平均値を安息角とする。
安息角を測定後、安息角テーブルユニット(部品番号:MT-1028)の下についている鍾をゆっくりタッピングテーブルの下まで持ち上げて落下させる。この操作を3回繰り返す。安息角の測定方法と同様の方法で3ヶ所の角度を読み、それらの相加平均値を崩壊角とする。
使用機器:マルチテスターMT-1001T型(セイシン企業社製)
ふるい:1.18mm
振動幅:0.7~0.8mm
結晶容量:100mL
スペーサー:32mm
タッピング速度:1回/秒
タッピング回数:400回
密比容の測定方法の具体例:0.7~0.8mmの幅で振動させた1.18mmのふるいを経由して結晶を落下させながら、補助円筒を装着したステンレス製の100mL円筒形容器に充填する。32mmのスペーサーを挟んで1回/秒のタッピングを400回繰り返した後に補助円筒を外し、容器の上面から過剰の粉体を注意深く擦り落とし、あらかじめ測定しておいた空の測定容器の質量を差し引くことで、粉体の質量を測定する。測定は独立して3回行い、平均値を求める。
安息角と崩壊角の差が大きい結晶は噴流性が高く制御が困難であるため、安息角と崩壊角の差は小さいことが好ましい。
使用機器:検出器(L-7405)、ポンプ(L-7100)、オートサンプラー(L-7200)、カラムオーブン(L-2350)(いずれも日立製作所社製)、クロマトパック(C-R8A)、データ解析(PACsolution)(いずれも島津製作所社製)
検出器:紫外吸光光度計(測定波長254nm)
カラム:Partisil 10SAX 粒径10μm 4.0×250mmを2本直列連結(Hichrom)
移動相:リン酸でpH3.5に調整された0.06mol/Lのリン酸二水素カリウム水溶液(リン酸二水素カリウム40.83gを蒸留水に溶解させ、リン酸を加えてpH3.5に調整した後に蒸留水で5000mLに調整)
カラム温度:30℃
流速:0.4~0.5mL/min(シチジンジリン酸コリンの保持時間が約26minになるように調整)
試料注入量:20μL
試料調製方法:シチジンジリン酸コリンの結晶を約0.1g秤量し、蒸留水に溶解させて100mLに調整したものを試料とする。
本発明の結晶の製造方法は、シチジンジリン酸コリンが溶解している水溶液にシチジンジリン酸コリンの結晶を析出させる工程、該析出したシチジンジリン酸コリンの結晶を採取する工程、及び該採取したシチジンジリン酸コリンの結晶を、含水量が5~50体積%である、メタノール以外の有機溶媒を含有する水溶液で洗浄する工程、を含む、シチジンジリン酸コリンの結晶の製造方法である。
シチジンジリン酸コリンが溶解している水溶液に含有されるシチジンジリン酸コリンは、発酵法、酵素法、天然物からの抽出法、化学合成法等のいずれの製造方法によって製造されたものであってもよい。
該種晶を添加する時間としては、例えば、メタノール以外の有機溶媒又は該有機溶媒を含有する水溶液の滴下又は添加を開始してから、好ましくは0~12時間以内、より好ましくは0~8時間以内、最も好ましくは0~4時間以内を挙げることができる。
結晶を成長させるとは、析出した結晶を元にして、結晶を増大させることをいう。
結晶の熟成は、結晶を成長させることを主な目的として行うが、結晶の成長と同時に、新たな結晶の析出が起こっていてもよい。
結晶を熟成させた後は、シチジンジリン酸コリンの結晶を析出させる工程を再開してもよい。
本発明の製造方法の一態様は、採取したシチジンジリン酸コリンの結晶を、含水量が5~50体積%、好ましくは10~40体積%、より好ましくは20~30体積%の、メタノール以外の有機溶媒を含有する水溶液で洗浄する。当該工程により、結晶への母液の付着を低減し、結晶の品質を向上させることに加えて、結晶の粉体物性を制御することができる。
日本国特公昭51-32630号公報(特許文献2)の実施例1に従い、760gのシチジンジリン酸コリン(協和発酵バイオ社製:Lot.160325)を蒸留水に溶かして1600mLとし、シチジンジリン酸コリンを450g/Lの濃度で含む水溶液を調製した。そのうちの400mLに対し、20℃にて1600mLのメタノールを20分かけて添加した。メタノールの添加中に白濁が見られた時点で、0.8gのシチジンジリン酸コリンを種晶として添加した。
比較例1で得られた結晶スラリーの残りを遠心分離にかけて結晶を濾別し、得られた湿晶を160mLの99.5体積%のエタノールに懸濁して撹拌することで、結晶表面に付着したメタノールを完全に洗い流した。この湿晶を減圧条件下、25℃にて3時間、さらに減圧条件下、60℃にて3時間乾燥させ、13.2gの結晶を得た。
日本国特許第647367号公報(特許文献3)の実施例3に従い、乾物換算で639.9gのシチジンジリン酸コリン(協和発酵バイオ社製:Lot.160325)を1300mLの蒸留水に加えて溶解したところ、1690mLの水溶液となった。このうちの832mLに対し、70℃にて640mLの99.5体積%のエタノールを混合した。続いて、この混合液を70℃に保ったまま1280mLの80体積%の含水エタノールを2時間かけて添加した。
比較例3と同じ方法で調製したシチジンジリン酸コリンの水溶液1040mLを30℃に保ち、800mLの99.5体積%のエタノールを混合した。この混合液に対し、30℃にて1600mLの99.5体積%のエタノールを2時間かけて添加した。その後、1.6gのシチジンジリン酸コリンを種晶として添加し、起晶を確認したのち、1600mLの99.5体積%のエタノールを2時間かけて添加した。
50~80体積%の含水エタノール(含水量20~50体積%)にシチジンジリン酸コリン(協和発酵バイオ社製:Lot.160325)を溶け残るまで溶解させ、30℃、35℃ 又は40℃にて十分に攪拌した。その後、各溶液をフィルター濾過し、得られた各濾液中のシチジンジリン酸コリン濃度(g/L)を測定した。結果を表1に示す。
比較例3で得られた結晶スラリーの1/3分を遠心分離にかけて結晶を濾別したのち、10℃に冷却した533mLの85体積%の含水エタノール(含水量15体積%)で洗浄した。得られた湿晶を減圧条件下、30℃にて3時間、さらに減圧条件下、60℃にて3時間乾燥させ、68.2gの結晶を得た。
比較例3で得られた結晶スラリーの1/3分を遠心分離にかけて結晶を濾別したのち、10℃に冷却した533mLの70体積%の含水エタノール(含水量30体積%)で洗浄した。得られた湿晶を減圧条件下、30℃にて3時間、さらに減圧条件下、60℃にて3時間乾燥させ、82.5gの結晶を得た。
比較例4で得られた結晶スラリーの1/3分を遠心分離にかけて結晶を濾別したのち、10℃に冷却した670mLの85体積%の含水エタノール(含水量15体積%)で洗浄した。得られた湿晶を減圧条件下、30℃にて3時間、さらに減圧条件下、60℃にて3時間乾燥させ、109.6gの結晶を得た。
比較例4で得られた結晶スラリーの1/3分を遠心分離にかけて結晶を濾別したのち、10℃に冷却した670mLの70体積%の含水エタノール(含水量30体積%)で洗浄した。得られた湿晶を減圧条件下、30℃にて3時間、さらに減圧条件下、60℃にて3時間乾燥させ、105.8gの結晶を得た。
Claims (11)
- メタノールを含有せず、かつ粗比容が4.1mL/g以下である、シチジンジリン酸コリンの結晶。
- 安息角が57度以下である、請求項1に記載の結晶。
- 崩壊角が50度以下である、請求項1又は2に記載の結晶。
- 密比容が2.1mL/g以下である、請求項1~3のいずれか1項に記載の結晶。
- エタノール、アセトン、1-プロパノール、2-プロパノール、酢酸エチル、1-ブタノール、2-ブタノール、ヘプタン、酢酸イソプロピル、メチルエチルケトン、酢酸プロピル及びテトラヒドロフランからなる群より選ばれる少なくとも1の有機溶媒以外の有機溶媒を含有しない、請求項1~4のいずれか1項に記載の結晶。
- エタノール、アセトン、1-プロパノール及び2-プロパノールからなる群より選ばれる少なくとも1の有機溶媒以外の有機溶媒を含有しない、請求項1~5のいずれか1項に記載の結晶。
- エタノール以外の有機溶媒を含有しない、請求項1~6のいずれか1項に記載の結晶。
- シチジンジリン酸コリンが溶解している水溶液にシチジンジリン酸コリンの結晶を析出させる工程、該析出したシチジンジリン酸コリンの結晶を採取する工程、及び該採取したシチジンジリン酸コリンの結晶を、含水量が5~50体積%である、メタノール以外の有機溶媒を含有する水溶液で洗浄する工程を含む、シチジンジリン酸コリンの結晶の製造方法。
- メタノール以外の有機溶媒が、エタノール、アセトン、1-プロパノール、2-プロパノール、酢酸エチル、1-ブタノール、2-ブタノール、ヘプタン、酢酸イソプロピル、メチルエチルケトン、酢酸プロピル及びテトラヒドロフランからなる群より選ばれる少なくとも1の有機溶媒である、請求項8に記載の製造方法。
- メタノール以外の有機溶媒が、エタノール、アセトン、1-プロパノール及び2-プロパノールからなる群より選ばれる少なくとも1の有機溶媒である、請求項8又は9に記載の製造方法。
- メタノール以外の有機溶媒がエタノールである、請求項8~10のいずれか1項に記載の製造方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017341136A AU2017341136B2 (en) | 2016-10-06 | 2017-10-06 | Crystal of cytidine diphosphate choline and production method thereof |
CN201780061184.4A CN109790197A (zh) | 2016-10-06 | 2017-10-06 | 胞苷二磷酸胆碱的晶体及其制造方法 |
EP17858526.1A EP3524613B1 (en) | 2016-10-06 | 2017-10-06 | Crystal of cytidine diphosphate choline and production method thereof |
JP2018543989A JP7146640B2 (ja) | 2016-10-06 | 2017-10-06 | シチジンジリン酸コリンの結晶及びその製造方法 |
US16/339,301 US11186605B2 (en) | 2016-10-06 | 2017-10-06 | Crystal of cytidine diphosphate choline and production method thereof |
CN202310942771.1A CN117069780A (zh) | 2016-10-06 | 2017-10-06 | 胞苷二磷酸胆碱的晶体及其制造方法 |
RU2019112721A RU2800932C2 (ru) | 2016-10-06 | 2017-10-06 | Кристалл цитидиндифосфатхолина и способ его получения |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-197695 | 2016-10-06 | ||
JP2016197695 | 2016-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018066690A1 true WO2018066690A1 (ja) | 2018-04-12 |
Family
ID=61831163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/036463 WO2018066690A1 (ja) | 2016-10-06 | 2017-10-06 | シチジンジリン酸コリンの結晶及びその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11186605B2 (ja) |
EP (1) | EP3524613B1 (ja) |
JP (1) | JP7146640B2 (ja) |
CN (2) | CN109790197A (ja) |
AU (1) | AU2017341136B2 (ja) |
WO (1) | WO2018066690A1 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687932A (en) * | 1969-04-24 | 1972-08-29 | Takeda Chemical Industries Ltd | Crystalline cytidine-5{40 -diphosphate choline monohydrate and production thereof |
JPS5132630B1 (ja) | 1971-06-08 | 1976-09-14 | ||
JPS51108076A (en) * | 1975-03-15 | 1976-09-25 | Asahi Chemical Ind | 2**3**00 surufuinirupirimijinnukureoshido 5** rinsanesuterujudotainoseizohoho |
JPS647367A (en) | 1987-03-31 | 1989-01-11 | Canon Kk | Method and device for recording information |
JP3369236B2 (ja) | 1992-01-30 | 2003-01-20 | 協和醗酵工業株式会社 | シチジンジリン酸コリンの製造法 |
WO2007018259A1 (ja) * | 2005-08-10 | 2007-02-15 | Kyowa Hakko Kogyo Co., Ltd. | シチジンジリン酸コリンの精製方法 |
WO2008047792A1 (fr) * | 2006-10-16 | 2008-04-24 | Kyowa Hakko Bio Co., Ltd. | Cristal de glutathione et son procédé de fabrication |
CN101538300A (zh) * | 2008-03-19 | 2009-09-23 | 南京工业大学 | 一种胞二磷胆碱的盐析-溶析结晶方法 |
JP2016197695A (ja) | 2015-04-06 | 2016-11-24 | 旭硝子株式会社 | 太陽電池モジュール |
JP6166786B2 (ja) | 2012-10-30 | 2017-07-19 | 協和発酵バイオ株式会社 | 脳機能低下の予防または改善剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI394753B (zh) | 2006-03-17 | 2013-05-01 | Otsuka Pharma Co Ltd | 新穎替妥牟拉(tetomilast)晶體 |
JP2012522792A (ja) | 2009-04-01 | 2012-09-27 | プリバ フルバトゥスカ ドゥ.オ.オ. | エルトロンボパグ及びエルトロンボパグ塩の多形体、並びにその調製方法 |
CN103319504A (zh) | 2013-06-28 | 2013-09-25 | 华北制药河北华民药业有限责任公司 | 一种头孢噻肟钠的结晶方法 |
-
2017
- 2017-10-06 CN CN201780061184.4A patent/CN109790197A/zh active Pending
- 2017-10-06 WO PCT/JP2017/036463 patent/WO2018066690A1/ja unknown
- 2017-10-06 AU AU2017341136A patent/AU2017341136B2/en active Active
- 2017-10-06 CN CN202310942771.1A patent/CN117069780A/zh active Pending
- 2017-10-06 US US16/339,301 patent/US11186605B2/en active Active
- 2017-10-06 EP EP17858526.1A patent/EP3524613B1/en active Active
- 2017-10-06 JP JP2018543989A patent/JP7146640B2/ja active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687932A (en) * | 1969-04-24 | 1972-08-29 | Takeda Chemical Industries Ltd | Crystalline cytidine-5{40 -diphosphate choline monohydrate and production thereof |
JPS5132630B1 (ja) | 1971-06-08 | 1976-09-14 | ||
JPS51108076A (en) * | 1975-03-15 | 1976-09-25 | Asahi Chemical Ind | 2**3**00 surufuinirupirimijinnukureoshido 5** rinsanesuterujudotainoseizohoho |
JPS647367A (en) | 1987-03-31 | 1989-01-11 | Canon Kk | Method and device for recording information |
JP3369236B2 (ja) | 1992-01-30 | 2003-01-20 | 協和醗酵工業株式会社 | シチジンジリン酸コリンの製造法 |
WO2007018259A1 (ja) * | 2005-08-10 | 2007-02-15 | Kyowa Hakko Kogyo Co., Ltd. | シチジンジリン酸コリンの精製方法 |
JP4977608B2 (ja) | 2005-08-10 | 2012-07-18 | 協和発酵バイオ株式会社 | シチジンジリン酸コリンの精製方法 |
WO2008047792A1 (fr) * | 2006-10-16 | 2008-04-24 | Kyowa Hakko Bio Co., Ltd. | Cristal de glutathione et son procédé de fabrication |
CN101538300A (zh) * | 2008-03-19 | 2009-09-23 | 南京工业大学 | 一种胞二磷胆碱的盐析-溶析结晶方法 |
JP6166786B2 (ja) | 2012-10-30 | 2017-07-19 | 協和発酵バイオ株式会社 | 脳機能低下の予防または改善剤 |
JP2016197695A (ja) | 2015-04-06 | 2016-11-24 | 旭硝子株式会社 | 太陽電池モジュール |
Non-Patent Citations (2)
Title |
---|
CYTIDINE 5' -DIPHOSPHATE CHOLINE MONOHYDRATE, vol. 34, no. 3, 1975, pages 358 - 368, XP9515009 * |
YAMAGISHI, TAKAMICHI: "Passage, A Laboratory Guide to Organic Chemical Experiment for Young Chemists", A LABORATORY GUIDE TO ORGANIC CHEMICAL EXPERIMENT FOR YOUNG CHEMISTS, 10 March 2010 (2010-03-10), pages 132 - 133, XP009515254, ISBN: 978-4-06-154375-1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3524613A1 (en) | 2019-08-14 |
EP3524613B1 (en) | 2024-04-03 |
JP7146640B2 (ja) | 2022-10-04 |
CN117069780A (zh) | 2023-11-17 |
AU2017341136B2 (en) | 2021-07-08 |
EP3524613A4 (en) | 2020-06-17 |
RU2019112721A (ru) | 2020-11-06 |
US11186605B2 (en) | 2021-11-30 |
JPWO2018066690A1 (ja) | 2019-07-25 |
AU2017341136A1 (en) | 2019-05-02 |
RU2019112721A3 (ja) | 2021-01-26 |
US20190225642A1 (en) | 2019-07-25 |
EP3524613C0 (en) | 2024-04-03 |
CN109790197A (zh) | 2019-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018047715A1 (ja) | β-ニコチンアミドモノヌクレオチドの結晶及びその製造方法 | |
US10745432B2 (en) | Crystal of 6′-sialyllactose sodium salt, and process for producing same | |
CN100379723C (zh) | 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 | |
JP4870787B2 (ja) | フコキサンチンおよび/またはフコステロールの製造方法 | |
WO2018066690A1 (ja) | シチジンジリン酸コリンの結晶及びその製造方法 | |
CN104861014A (zh) | 一种盐酸表阿霉素结晶的制备方法 | |
CN103183587B (zh) | 3,3’,5,5’-四异丙基-4,4’-二联苯酚的新晶型及其制备方法 | |
CN102557918B (zh) | 一种布洛芬钠化合物及其制法 | |
RU2800932C2 (ru) | Кристалл цитидиндифосфатхолина и способ его получения | |
EP3617191A1 (en) | Method for manufacturing diastereomer of citric acid derivative | |
US20200369721A1 (en) | Crystal of reduced glutathione and method for producing same | |
US11365170B2 (en) | Non-solvate crystal of eucomic acid and method for producing same | |
JP2018203690A (ja) | L−カルノシンの結晶及びその製造方法 | |
JP7069040B2 (ja) | L-アラニル-l-グルタミンの結晶及びその製造方法 | |
CN105287409A (zh) | 治疗老年痴呆的药物盐酸甲氯芬酯组合物冻干粉针剂 | |
WO2017195743A1 (ja) | 3'-シアリルラクトースナトリウム塩・n水和物の結晶及びその製造方法 | |
CN109020995A (zh) | 一种替西罗莫司的晶型物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17858526 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018543989 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017341136 Country of ref document: AU Date of ref document: 20171006 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017858526 Country of ref document: EP Effective date: 20190506 |